Atacicept hits in phase 2, but uncompetitive data are seen as good news for its IgAN rivals.
Bayer dumps Atara, Precigen prepares for a fire sale and Tmunity struggles to find direction. Should investors still be excited about cell therapy?
Astrazeneca/Daiichi’s Enhertu and Roche’s Polivy both score in pivotal trials that could see them threaten early-line incumbents.
China’s answer to the Asco conference, remarkably now in its 22nd year, reminds western investors of the country’s oncology prowess.